Entrada Therapeutics, Inc.
TRDA evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $250.0M
- Lead Asset:
- entr-601-44 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for TRDA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TRDA
Entrada Therapeutics, Inc. (TRDA) is a biotech company developing genetic medicines for neuromuscular and inherited retinal diseases using proprietary endosomal escape vehicle technology.
Key risk: Cash burn rate
BioSniper Score
Based on 4 of 6 signals
Market Cap
$250.0M
Cash Runway
—
Lead Asset
entr-601-44 (Phase 1/Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 3 clinical trials for Entrada Therapeutics, Inc..
Entrada Therapeutics, Inc. (TRDA) is a biotech company developing genetic medicines for neuromuscular and inherited retinal diseases using proprietary endosomal escape vehicle technology.
- Cash & equivalents of $99.3M as of 2026-06-30 [sec]
- Total revenue of $0.9M and net income of -$42.8M as of 2026-06-30 [sec]
- Shareholders' equity of $233.4M as of 2026-06-30 [sec]
- Advancing ELEVATE-44 and ELEVATE-45 clinical trials for Duchenne muscular dystrophy [sec_mda · as of 2026-08-05]
- VX-670 partnership with Vertex Pharmaceuticals progressing, with results expected in H2 2026 [sec_mda · as of 2026-08-05]
What works
- Proprietary endosomal escape vehicle platform enables targeting of historically inaccessible intracellular targets [sec_mda · as of 2026-08-05]
- Portfolio diversification into ocular diseases with first candidate ENTR-801 for Usher syndrome type 2A [sec_mda · as of 2026-08-05]
- Multiple clinical-stage programs in DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50) [sec_mda · as of 2025-11-06]
- Vertex partnership provides external validation and potential milestone payments [sec_mda · as of 2026-08-05]
What to weigh
- Low revenue of $0.9M and net loss of -$42.8M as of 2026-06-30 [sec]
- Only low single digit competitive dystrophin production observed to date in DMD programs [sec_mda · as of 2026-08-05]
- Cash runway estimated into Q3 2027 based on $295.7M as of Dec 2025, but cash burn rate is high [sec_mda · as of 2026-02-26]
- Clinical data still early-stage; no approved products yet [sec_mda · as of 2026-08-05]
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2025-06-30 · Phase 2 start for ENTR-601-44 (ELEVATE-44) — Initiation of a 2-part, randomized, double-blind, placebo-controlled study in DMD patients amenable to exon 44 skipping.
- 2025-08-30 · Phase 2 start for ENTR-601-45 (ELEVATE-45) — Initiation of a similar study for exon 45 skipping in DMD patients.
Risks & what to watch (3)›
Key risks
- Cash burn rate — Cash decreased from $295.7M (Dec 2025) to $99.3M (Jun 2026), indicating high burn [sec]
- Clinical data uncertainty
- Regulatory approval risk
What to watch
- Vertex VX-670 results expected H2 2026 [sec_mda · as of 2026-08-05]
- ELEVATE-44-201 Cohort 1 open-label data expected by end of 2026 [sec_mda · as of 2026-08-05]
- Second ocular clinical candidate announcement in H2 2026 [sec_mda · as of 2026-08-05]
- Regulatory submissions for ENTR-601-50 and ENTR-601-51 [sec_mda · as of 2026-08-05]
Sources: Catalysts · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Entrada Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Entrada Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.28 · 0% dilution
Lead: Phase 1/Phase 2
5 candidates
No upcoming catalysts tracked
1 buy · 17 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
119
Total value held
$310.4M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 5,072,730 | $64.0M |
| 5am venture management, llc | 4,056,379 | $51.2M |
| blackrock, inc. | 2,358,793 | $29.8M |
| tcg crossover management, llc | 2,287,500 | $28.9M |
| vanguard capital management llc | 1,256,013 | $15.9M |
| wellington management group llp | 1,034,782 | $13.1M |
| stepstone group lp | 761,277 | $9.6M |
| geode capital management, llc | 667,347 | $8.4M |
| state street corp | 533,798 | $6.7M |
| millennium management llc | 519,356 | $6.6M |
Showing top 10 of 119 institutional holders of Entrada Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 4.3%
- Days to cover
- 3.9
- Shares short
- 894,152
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TRDA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Entrada Therapeutics, Inc.?
Entrada Therapeutics, Inc. (TRDA) is a biotech company developing genetic medicines for neuromuscular and inherited retinal diseases using proprietary endosomal escape vehicle technology.
What is Entrada Therapeutics, Inc.'s lead drug candidate?
Entrada Therapeutics, Inc.'s most advanced tracked candidate is entr-601-44 (Phase 1/Phase 2) for Duchenne Muscular Dystrophy (DMD).
Who is the CEO of Entrada Therapeutics, Inc.?
Mr. Dipal Doshi is the chief executive officer of Entrada Therapeutics, Inc. (TRDA).
Where is Entrada Therapeutics, Inc. headquartered?
Entrada Therapeutics, Inc. (TRDA) is headquartered in Boston, MA, United States.
What therapeutic areas does Entrada Therapeutics, Inc. focus on?
Entrada Therapeutics, Inc. develops therapies across Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.